Novo Nordisk's Victoza® Found Superior Than Januvia®

Filed in archive Research , Treatment on June 27, 2010

Novo Nordisk's Victoza®

Research data presented at the recent 70th Annual Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-daily Victoza® (liraglutide by Novo Nordisk) - in combination with metformin- produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) as compared to Januvia® (sitagliptin by Merck) plus metformin at 52 weeks.

Victoza® - the first human Glucagon-Like Peptide-1 (GLP-1) analogue - is an injectable prescription medicine used for the improvement of blood sugar (glucose) in adults with type 2 diabetes along with diet and exercise.

Approved by the US FDA sometime in January 2010 ( in combination with diet and exercise) to improve blood sugar control in adults with type 2 diabetes, Victoza® (liraglutide) works by stimulating the beta cells in the body in order to release insulin but only when blood sugar levels are high.